Health Care & Life Sciences » Biotechnology | Rich Pharmaceuticals Inc.

Rich Pharmaceuticals Inc. | Income Statement

Fiscal year is April-March. All values USD Thousands.
2013
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
115.00
Cost of Goods Sold (COGS) incl. D&A
-
0.50
0.80
1.60
-
Gross Income
-
0.50
0.80
1.60
-
SG&A Expense
31.40
3,523.80
1,116.80
950.20
1,450.20
EBIT
31.40
3,524.30
1,117.60
951.80
1,336.40
Unusual Expense
-
1,791.50
563.40
1,183.00
1,213.20
Non Operating Income/Expense
-
1,839.90
497.20
609.00
52.00
Interest Expense
-
560.90
717.10
497.50
1,621.10
Pretax Income
31.40
4,133.60
1,768.50
3,241.30
1,692.30
Consolidated Net Income
31.40
4,133.60
1,768.50
3,241.30
1,692.30
Net Income
31.40
4,133.60
1,768.50
3,241.30
1,692.30
Net Income After Extraordinaries
31.40
4,133.60
1,768.50
3,241.30
1,692.30
Net Income Available to Common
31.40
4,133.60
1,768.50
3,241.30
1,692.30
EPS (Basic)
20.00
20.00
0.40
0.08
0.00
Basic Shares Outstanding
1.30
316.60
3,801.10
41,403.50
763,472.00
EPS (Diluted)
23.89
13.06
0.47
0.08
0.00
Diluted Shares Outstanding
1.30
316.60
3,801.10
41,403.50
763,472.00
EBITDA
31.40
3,523.80
1,116.80
950.20
1,335.20

About Rich Pharmaceuticals

View Profile
Address
145 South Fairfax Avenue
Los Angeles California 90036
United States
Employees -
Website http://www.richpharmaceuticals.com
Updated 07/08/2019
Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages on developing innovative therapies in oncology. It develops RP-323 for the treatment of Hodgkin's lymphoma, Acute Myelogenous Leukemia, and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. The company was founded on August 9, 2010 and is headquartered in Beverly Hills, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.